Sandra Levy
ARTICLES BY THIS AUTHOR
- 11/29/2021
Seqirus receives FDA nod for new Audenz presentation
The FDA approved Seqirus’ multidose vial presentation for Audenz to help protect individuals aged six months old and older against influenza A(H5N1) in the event of a pandemic. - 11/29/2021
CVS Pharmacy takes Spoken Rx labels nationwide
Spoken Rx, designed for people with visual impairments or who cannot read standard print labels, uses technology that reads prescription information out loud. - 11/29/2021
Walgreens Boots Alliance attains remaining stake in McKesson’s GEHE, Alliance Healthcare ventures
Walgreens Boots Alliance will become the owner of the combined GEHE and Alliance Healthcare businesses in Germany. - 11/28/2021
Mayne Pharma names new board member
Carolyn Myers, who has experience in business development, sales, marketing, strategy and portfolio management, has led the launch of more than 20 brand products. - 11/28/2021
CVS Health pledges $7.7M investment in affordable housing for Tampa, Fla.
CVS Health will invest $7.7 million with Raymond James Tax Credit Funds to build a 61 unit multifamily apartment home development called Uptown Sky in Tampa, Fla. - 11/28/2021
BioTek reMEDys to provide Uplizna
Uplizna is used to treat adults with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive. - 11/28/2021
Industry Issues Summit panel weighs in on how focusing on patients can improve outcomes
The first panel of DSN’s annual Industry Issues Summit highlighted how a laser focus on patients can drive improved outcomes. - 11/28/2021
Walmart’s CFO to depart
Brett Biggs will remain in the CFO role until a successor is named in 2022. He will support the role transition by remaining an associate until Jan. 31, 2023. - 11/22/2021
Amneal receives FDA nod for generic Durezol
Durezol and its generics had a market value of roughly $103 million in the 12 months ended September 2021, according to IQVIA. - 11/22/2021
AAM: Inflation rebate proposal threatens seniors’ access to generics
The organization noted that inflation-based rebates can exacerbate existing shortages, limit access to life-saving treatments, and jeopardize the sustainability of the generics market and its role in holding down drug costs.
